Fibroblast activation protein targeted therapy using [<sup>177</sup>Lu]FAPI-46 compared with [<sup>225</sup>Ac]FAPI-46 in a pancreatic cancer model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34537893.
- Also identified by DOI 10.1007/s00259-021-05554-2 and PMC identifier 8803706.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Fibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study used <sup>64</sup>Cu and <sup>225</sup>Ac-labelled FAP inhibitors (FAPI-04) for a FAP-expressing pancreatic cancer xenograft imaging and therapy. However, the optimal therapeutic radionuclide for FAPI needs to be investigated further. In this study, we evaluated the therapeutic effects of beta-emitter (<sup>177</sup>Lu)-labelled FAPI-46 and alpha-emitter (<sup>225</sup>Ac)-labelled FAPI-46 in pancreatic cancer models. PET scans (1 h post injection) were acquired in PANC-1 xenograft mice (n = 9) after the administration of [<sup>18</sup>F]FAPI-74 (12.4 ± 1.7 MBq) for the companion imaging. The biodistribution of [<sup>177</sup>Lu]FAPI-46 and [<sup>225</sup>Ac]FAPI-46 were evaluated in the xenograft model (total n = 12). For the determination of treatment effects, [<sup>177</sup>Lu]FAPI-46 and [<sup>225</sup>Ac]FAPI-46 were injected into PANC-1 xenograft mice at different doses: 3 MBq (n = 6), 10 MBq (n = 6), 30 MBq (n = 6), control (n = 4) for [<sup>177</sup>Lu]FAPI-46, and 3 kBq (n = 3), 10 kBq (n = 2), 30 kBq (n = 6), control (n = 7) for [<sup>225</sup>Ac]FAPI-46. Tumour sizes and body weights were followed. [<sup>18</sup>F]FAPI-74 showed rapid clearance by the kidneys and high accumulation in the tumour and intestine 1 h after administration. [<sup>177</sup>Lu]FAPI-46 and [<sup>225</sup>Ac]FAPI-46 also showed rapid clearance by the kidneys and relatively high accumulation in the tumour at 3 h. Both [<sup>177</sup>Lu]FAPI-46 and [<sup>225</sup>Ac]FAPI-46 showed tumour-suppressive effects, with a mild decrease in body weight. The treatment effects of [<sup>177</sup>Lu]FAPI-46 were relatively slow but lasted longer than those of [<sup>225</sup>Ac]FAPI-46. This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.
Medical subject headings
- Pancreatic Neoplasms